Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis pill shows promise in large trial

NCT ID NCT06586112

Disease control Sponsor: Alumis Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study tested whether a new daily pill, ESK-001, can safely reduce psoriasis severity in adults with moderate to severe plaque psoriasis. Over 900 participants took either ESK-001, a placebo (dummy pill), or an approved psoriasis drug (apremilast) for 24 weeks. Researchers measured skin clearing and monitored side effects to see if ESK-001 works better than placebo and how it compares to existing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

912 people

The number who actually took part.

Started

Jul 2024

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or females, age ≥18 years 2. Diagnosis of plaque psoriasis for ≥6 months 3. Plaques covering ≥10% of BSA 4. PASI ≥12 5. sPGA ≥3 6. Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception Exclusion Criteria: 1. Nonplaque psoriasis or other inflammatory skin conditions 2. immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Participants with psoriatic arthritis may participate 3. Pregnant, lactating, or planning to get pregnant during the study 4. Use of drugs prior to Study Day 1 that treat or may affect psoriasis: * Topical within 2 weeks * Phototherapy or any systemic treatments within 4 weeks * Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months * Systemic immunosuppressants or immunomodulatory drugs within 4 weeks * Modulators of B cells within 6 months, or T cells within 3 months * JAK inhibitors or TYK2 inhibitors within 4 weeks * PDE4 inhibitor within 2 months * Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study 5. Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment 6. Participants with QTcF \>450 msec (males) or \>470 msec (females) at Screening 7. Unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months 8. Evidence of recent or recurrent herpes zoster or herpes simplex viral infection 9. Evidence of active infection or positive test result for hepatitis B, hepatitis C, HIV or TB 10. History of serious bacterial, fungal, or viral infections that led to hospitalization, or any recent serious infection requiring antibiotic treatment 11. Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status 12. Lab abnormalities indicating significant renal, hepatic or bone marrow dysfunction 13. History of any immune-mediated or inflammatory medical condition for which participants requires current systemic corticosteroids \* Stable doses of inhaled corticosteroids for treatment of asthma are allowed 14. Known current malignancy or current evaluation for a potential malignancy or history of malignancy within the past 5 years prior to screening, except for adequately treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix 15. Live vaccines within 4 weeks prior to Study Day 1 16. Participant has planned surgery during the study period 17. Any acute or chronic illness/condition or evidence of an unstable clinical condition that, in the opinion of the Investigator, will substantially increase the risk to the participant if he or she participates in the study 18. History of mental illness within the last 5 years, unless receiving a fixed regimen of psychiatric medications for at least 6 months before screening or has not required or been prescribed any psychiatric medication within 12 months before screening 19. Evidence of severe depressive symptoms or active suicidal ideation or behavior

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • "Centre de Recherche Dermatologique du Quebec Metropolitain Inc."

    Québec, Quebec, G1V 4X7, Canada

  • AES Gdansk

    Gdansk, Pomeranian Voivodeship, 80-382, Poland

  • Alliance Clinical Trials

    Waterloo, Ontario, N2J 1C4, Canada

  • Alliance Dermatology

    Phoenix, Arizona, 85032, United States

  • Arlington Dermatology

    Rolling Meadows, Illinois, 60008, United States

  • Asahikawa Medical University Hospital

    Asahikawa, Hokkaido, 078-8510, Japan

  • Austin Institute for Clinical Research - Houston

    Houston, Texas, 77056, United States

  • CCR Ostrava, s.r.o.

    Ostrava, 70200, Czechia

  • Caban Skin Institute

    Tampa, Florida, 33607, United States

  • California Dermatology & Clinical Research Institute

    Encinitas, California, 92024-7700, United States

  • California Dermatology Institute - Thousand Oaks

    Thousand Oaks, California, 91320-2130, United States

  • Canadian Dermatology Centre

    Toronto, Ontario, M3B 0A7, Canada

  • Center for Clinical Studies - Texas Medical Center

    Houston, Texas, 77004, United States

  • Centricity Research

    London, Ontario, N6A 2C2, Canada

  • Centrum Badań Klinicznych PI House Sp. Z O.O.

    Gdansk, 80-546, Poland

  • Centrum Medyczne Angelius Provita (Angelius Provita Medical Centre)

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Centrum Medyczne Pratia Bydgoszcz

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85796, Poland

  • Centrum Medyczne Reuma Park

    Warsaw, Masovian Voivodeship, 02-665, Poland

  • Centrum Medyczne Synexus Gdynia

    Gdynia, Pomeranian Voivodeship, 81-537, Poland

  • Centrum Medyczne Synexus Warszawa

    Warsaw, 02-672, Poland

  • Centrum Medyczne Synexus Wroclaw

    Wroclaw, Lower Silesian Voivodeship, 50-381, Poland

  • Chosun Universtiy Hospital

    Gwangju, Dong-gu, 61453, South Korea

  • Clearlyderm Dermatology - West Boca Raton

    Boca Raton, Florida, 33428, United States

  • Cleaver Dermatology

    Kirksville, Missouri, 63501-5362, United States

  • Clineca

    Stara Zagora, Stara Zagora, 6000, Bulgaria

  • ClinicMed Daniluk, Nowak Spolka Komandytowa

    Bialystok, Podlaskie Voivodeship, 15-879, Poland

  • Clintrial s.r.o.

    Prague, 100 00, Czechia

  • DERMAMEDICA, s.r.o.

    Náchod, 54701, Czechia

  • Dawes Fretzin Clinical Research Group

    Columbus, Indiana, 47201, United States

  • Derm Art Institute

    Gdynia, Pomeranian Voivodeship, 81-415, Poland

  • DermEdge Research

    Mississauga, Ontario, L4Y 4C5, Canada

  • DermEffects

    London, Ontario, N6H 5L5, Canada

  • Dermatologicka ambulance - Svitavy

    Svitavy, 568 02, Czechia

  • Dermatologie Sima Inc.

    Verdun, Quebec, H4G 3E7, Canada

  • Dermatologists of Southwestern Ohio, LLC

    Mason, Ohio, 45040-4520, United States

  • Dermatology and Ophthalmology Kume Clinic

    Osaka, Saka-Shi, 593-8324, Japan

  • Dermatology on Bloor

    Toronto, Ontario, M4W 2N4, Canada

  • Dermatrials Research Inc.

    Hamilton, Ontario, L8N 1Y2, Canada

  • Dermskin, s.r.o.

    Olomouc, Moravia, 77900, Czechia

  • Diagnostic Consultative Center Aleksandrovska EOOD

    Sofia, 1431, Bulgaria

  • Diamond Clinic

    Krakow, Malopolska, 31-559, Poland

  • Discover Dermatology, LLC d/b/a Cumberland Skin Center for Clinical Research under Objective Health

    Hermitage, Tennessee, 37076, United States

  • Discover Dermatology, LLC d/b/a Goodlettsville Dermatology Research

    Goodlettsville, Tennessee, 37072-2301, United States

  • Driven Clinical Research

    Coral Gables, Florida, 33134, United States

  • Dundee Dermatology

    West Dundee, Illinois, 60118, United States

  • Eberhard Karls Universitaet Tuebingen Universitaets Hautklinik Tuebingen

    Tübingen, Baden-Wurttemberg, 72070, Germany

  • Enverus Medical Research

    Surrey, British Columbia, V3V 0C6, Canada

  • Equity Medical - Bowling Green

    Bowling Green, Kentucky, 42104, United States

  • Exalt Clinical Research

    Chula Vista, California, 91910, United States

  • Fachklinik Bad Bentheim

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Fakultni Nemocnice Kralovske Vinohrady FNKV Dermatovenerologicka Klinika

    Prague, 10034, Czechia

  • Fakultni nemocnice Plzen Dermatovenerologicka klinika

    Pilsen, Bory, 301 00, Czechia

  • First OC Dermatology Research Inc

    Fountain Valley, California, 92708, United States

  • ForCare Medical Center

    Tampa, Florida, 33613-1244, United States

  • Frontier Dermatology

    Mill Creek, Washington, 98012, United States

  • Fukuoka University Hospital

    Fukuoka, Fukuoka-shi, 814-0180, Japan

  • FutureMeds Warszawa Centrum

    Warsaw, Masovian Voivodeship, 00215, Poland

  • Glick Skin Institute - Margate

    Margate, Florida, 33063-7011, United States

  • Hallym University Sacred Heart Hospital

    Anyang-si, Gyeonggi-do, 14068, South Korea

  • Hautarztpraxis Dr. Mihaescu

    Augsburg, Bavaria, 86150, Germany

  • Hautarztpraxis Mahlow

    Mahlow, Brandenburg, 15831, Germany

  • Hautarztpraxis an der Hase

    Bramsche, Lower Saxony, 49565, Germany

  • Health Concepts

    Rapid City, South Dakota, 57702-9208, United States

  • High Med Przychodnia Specjalistyczna

    Warsaw, Masovian Voivodeship, 01-817, Poland

  • Hokkaido University Hospital

    Hokkaido, Sapporo-shi, 060-8648, Japan

  • Hospital CUF Descobertas

    Lisbon, Lisbon District, 1998-018, Portugal

  • Hospital da Senhora da Oliveira

    Guimarães, Braga District, 4835-044, Portugal

  • Institute of Cosmetic & Laser Surgery

    Oakville, Ontario, L6J 7W5, Canada

  • Intramedis CSS

    Remscheid, North Rhine-Westphalia, 42897, Germany

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216, United States

  • Kanto Rosai Hospital

    Kanagawa, Kawasaki-shi, 211-8510, Japan

  • Kindai University Hospital

    Osaka, Sayama-Shi, 589-8511, Japan

  • Klinikum Bielefeld

    Bielefeld, North Rhine-Westphalia, 33647, Germany

  • Konkuk University Medical Center

    Seoul, Gwangjin-gu, 05030, South Korea

  • Kozni ambulance Kutna Hora, s.r.o.

    Kutná Hora, 28401, Czechia

  • LENUS Research

    Sweetwater, Florida, 33172, United States

  • Laser Clinic

    Szczecin, West Pomeranian Voivodeship, 70-332, Poland

  • Lynderm Research Inc.

    Markham, Ontario, L3P 1X3, Canada

  • MICS Medical Center Warsaw

    Warsaw, Masovian Voivodeship, 00-874, Poland

  • MUDr Radka Neumannova

    Svitavy, 56802, Czechia

  • Marvel Clinical Research, LLC

    Huntington Beach, California, 92647, United States

  • Medical Corporation Jitai kai Tachikawa Dermatology Clinic

    Tokyo, Tachikawa-shi, 190-0023, Japan

  • Medikal Center Kordis

    Pleven, 5800, Bulgaria

  • MetroBoston Clinical Partners

    Brighton, Massachusetts, 02135, United States

  • MetroMed Clinical Trials

    Chicago, Illinois, 60614-3625, United States

  • Mie University Hospital

    Mie, Tsu-shi, 514-8507, Japan

  • Multiprofile Hospital for Active Treatment Dr Tota Venkova

    Gabrovo, Gabrovo, 5300, Bulgaria

  • Nagoya City University Hospital

    Aichi, Nagoya-shi, 467-8602, Japan

  • National Hospital Organization Sagamihara National Hospital

    Kanagawa, Sagamihara, 252-0392, Japan

  • Nemocnice Nový Jičín, A.S.

    Nový Jičín, 74101, Czechia

  • Nihon University Itabashi Hospital

    Tokyo, Itabashi-Ku, 173-8610, Japan

  • Nippon Life Hospital

    Osaka, Osaka-Shi, 550-0006, Japan

  • North Eastern Health Specialists (NEHS)

    Campbelltown, South Australia, 5074, Australia

  • North York Research Inc.

    Toronto, Ontario, M2N3A6, Canada

  • NorthShore Medical Group - Dermatology - Skokie

    Skokie, Illinois, 60077-1049, United States

  • Northridge Clinical Trials - Elite Clinical Network

    Northridge, California, 91325, United States

  • Northwest Arkansas Clinical Trials Center (NWACTC), PLLC

    Rogers, Arkansas, 72758-8600, United States

  • Oceanic Research Group

    North Miami Beach, Florida, 33169, United States

  • Okayama University Hospital

    Okayama, Okayama-shi, 700-8558, Japan

  • Olive View - UCLA Education & Research Institute

    Sylmar, California, 91342, United States

  • OptiSkin

    New York, New York, 10128-0724, United States

  • Oregon Medical Research Center

    Portland, Oregon, 97201, United States

  • Osaka Metropolitan University Hospital

    Osaka, Osaka-shi, 545-8586, Japan

  • Osaka University Hospital

    Osaka, Suita-shi, 565-0871, Japan

  • Paddington Testing Company Inc.

    Philadelphia, Pennsylvania, 19103, United States

  • Pasadena Clinical Trials

    Pasadena, California, 91101, United States

  • Praglandia

    Prague, 15000, Czechia

  • Pratia Brno s.r.o.

    Brno, Moravia, 60200, Czechia

  • Pratia Małopolskie Centrum Medyczne (MCM) Kraków

    Krakow, 30-727, Poland

  • Pratia Pardubice a.s.

    Pardubice, 53002, Czechia

  • Pratia Prague, s.r.o.

    Prague, 13000, Czechia

  • Premier Specialists

    Kogarah, New South Wales, 2217, Australia

  • Pro Derma

    Dülmen, North Rhine-Westphalia, 48249, Germany

  • Pusan National University Hospital

    Busan, 49241, South Korea

  • Rejuvenation Medical Group Edmonton Downtown

    Edmonton, Alberta, T5J 3S9, Canada

  • Reveal Research Institute

    Frisco, Texas, 75033, United States

  • Rheuma Medicus

    Warsaw, 02-118, Poland

  • RoyalDerm

    Warsaw, Mazowiecke, 02-962, Poland

  • San Marcus Research Clinic, Inc - Miami

    Miami Lakes, Florida, 33014, United States

  • Sanatorium Profesora Arenbergera

    Prague, 110 00, Czechia

  • Saruwatari Dermatology Clinic

    Kagoshima, Kagoshima-Shi, 890-0046, Japan

  • Savin Medical Group LLC

    Miami Lakes, Florida, 33014, United States

  • Scottsdale Clinical Trials

    Scottsdale, Arizona, 85260, United States

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Sinclair Dermatology

    East Melbourne, Victoria, 3002, Australia

  • Siteworks

    Lohne, Lower Saxony, 49393, Germany

  • Skin Care Physicians of Georgia - Warner Robins

    Macon, Georgia, 31217, United States

  • Skin Health Institute Inc.

    Carlton, Victoria, 3053, Australia

  • Skin and Venereal Diseases Center EOOD

    Sofia, 1404, Bulgaria

  • Specjalistyczny Ośrodek Alergologiczno-Internistyczny "ALL-MED"

    Krakow, Lesser Poland Voivodeship, 30-033, Poland

  • Studies in Dermatology, LLC

    Cypress, Texas, 77429, United States

  • Sunwise Clinical Research, LLC

    Lafayette, California, 94549, United States

  • The Centre for Dermatology

    Richmond Hill, Ontario, L4B 1A5, Canada

  • The Ohio State University Wexner Medical Center (OSUWMC) - OSU Dermatology East - Columbus

    Gahanna, Ohio, 43230-5317, United States

  • The South Bend Clinic

    South Bend, Indiana, 46617, United States

  • Therapeutics Clinical Research

    San Diego, California, 92123, United States

  • Tokyo Medical University Hospital

    Tokyo, Shinjuku-Ku, 160-0023, Japan

  • Tulane University School of Medicine

    New Orleans, Louisiana, 70112, United States

  • UPMC Department of Dermatology

    Pittsburgh, Pennsylvania, 15213, United States

  • UT Health Houston Department of Dermatology

    Bellaire, Texas, 77401, United States

  • Unidade Local de Saude Santo Antonio Hospital de Santo Antonio

    Porto, Porto District, 4099-001, Portugal

  • Unison Clinical Trials/ Shahram Jacobs MD

    Sherman Oaks, California, 91403-1814, United States

  • Unity Clinical Research (UCR)

    Oklahoma City, Oklahoma, 73118, United States

  • Universitatsklinikum Frankfurt

    Frankfurt am Main, Hesse, 60590, Germany

  • Universitatsklinikum Schleswig-Holstein

    Kiel, Schleswig-Holstein, 24105, Germany

  • University of Utah Health Care - Midvalley Health Center

    Murray, Utah, 84107, United States

  • Velocity Clinical Research at The Dermatology Clinic, Baton Rouge

    Baton Rouge, Louisiana, 70808, United States

  • Velocity Clinical Research, Medford

    Medford, Oregon, 97504, United States

  • Velocity Clinical Research, Skierniewice

    Skierniewice, Łódź Voivodeship, 96-100, Poland

  • Vesalion sro

    Ostrava, 70200, Czechia

  • Wallace Medical Group Inc

    Los Angeles, California, 90056, United States

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

  • WroMedica

    Wroclaw, Lower Silesian Voivodeship, 51-685, Poland

  • Yamaguchi University Hospital

    Yamaguchi, Ube-shi, 755-8505, Japan

  • Yokohama City University Hospital

    Kanagawa, Yokohama-shi, 236-0004, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.